The Toll-Like Receptor 2 agonist PEG-Pam2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites
Both vaccine and therapeutic approaches to malaria are based on conventional paradigms; whole organism or single antigen epitope-based vaccines administered with or without an adjuvant, and chemotherapeutics (anti-malaria drugs) that are toxic to the parasite. Two major problems that limit the effec...
Main Authors: | Medard Ernest, Carol Hunja, Yuka Arakura, Yohei Haraga, Hussein M. Abkallo, Weiguang Zeng, David C. Jackson, Brendon Chua, Richard Culleton |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | International Journal for Parasitology: Drugs and Drug Resistance |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211320718300630 |
Similar Items
-
Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide
by: Giulia Franzoni, et al.
Published: (2021-06-01) -
Generation of adaptive immune responses following influenza virus challenge is not compromised by pre-treatment with the TLR-2 agonist Pam2Cys
by: Edin Jessica Mifsud, et al.
Published: (2015-06-01) -
Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs.
by: Martina Barrenschee, et al.
Published: (2010-11-01) -
Sulforaphane suppresses lipopolysaccharide‐ and Pam3CysSerLys4‐mediated inflammation in chronic obstructive pulmonary disease via toll‐like receptors
by: Xiaoli Zeng, et al.
Published: (2021-05-01) -
Study on the antioxidant enzymes 2-Cys and 1-Cys Peroxiredoxin
by: Hui-Ming Huang, et al.
Published: (2005)